Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer

OBJECTIVE: The glucocorticoid receptor (GR) promotes resistance to androgen receptor (AR)-targeting therapies in castration-resistant prostate cancer (CRPC) by bypassing AR blockade. However, the clinical relevance of evaluating GR expression in patients with CRPC has not been determined. The presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pak, Sahyun, Suh, Jungyo, Park, Seo Young, Kim, Yunlim, Cho, Yong Mee, Ahn, Hanjong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541428/
https://www.ncbi.nlm.nih.gov/pubmed/36212458
http://dx.doi.org/10.3389/fonc.2022.972572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541428/
https://www.ncbi.nlm.nih.gov/pubmed/36212458
http://dx.doi.org/10.3389/fonc.2022.972572

Ejemplares similares